GlobeNewsWire
13 Jul 2026, 17:52 UTC · 5h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Grail's NHS-Galleri Trial failed to observe a statistically significant reduction in Stage III-IV cancer. — The failure of a primary clinical endpoint for a core product typically leads to significant valuation drops and loss of investor confidence.
-0.80Grail is facing a securities fraud class action lawsuit alleging management made materially false or misleading statements regarding trial data. — Legal challenges and allegations of fraud create additional financial liability and reputational risk for the company.
-0.40Which stocks this story touches
The company is facing a securities fraud class action lawsuit following a 50.5% stock price drop due to failure to meet a primary trial endpoint.
Continue reading
6 related stories
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
